GASTROClear
GASTROClear™
GASTROClearProduct
GASTROClear™
No graph yet
Mentioned in 4 articles
Coverage
Congratulations to Mirxes on its successful listing on the Hong Kong Stock Exchange's Main Board — Gaorong Ventures was its earliest institutional investor.
A leading provider of molecular cancer screening products and services.
高榕创投·From Nobel Discovery to Clinical Application: Mirxes Is Transforming Cancer Early Screening with miRNA Technology | Gaorong Ventures
Focused on miRNA technology development, pioneering early cancer screening worldwide.
高榕创投·"Tiny but Mighty" miRNA: How Cancer Can Be Caught at Its Earliest Stage | Gaorong Ventures "Future"
By applying microRNA to early cancer screening, we can transform cancer from a terminal illness into a chronic disease that can be intercepted at an early stage.
高榕创投·Mirxes Completes $87 Million Series C Round to Develop Early Cancer Screening Products Based on Leading miRNA Technology
Focused on microRNA technology, dedicated to early disease diagnosis.
高榕创投·
